October 1, 2025 · Form 4 insider transaction
Dambkowski Carl sold 5,110 shares of Apogee Therapeutics, Inc. at $39.80 per share, a transaction worth $203.4K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.; The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.33 to $40.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.